Objective:To investigate the effectiveness of high-dose dexamethasone on children with immune thrombocytopenia (ITP). Methods:60 cases of newly diagnosed ITP were randomly divided into two groups, the treatment group with high-dose dexamethasone 1 mg·kg-1·d-1 treatment, the control group with routine dose of dexamethasone 0.25 mg·kg-1·d-1 treatment. The platelet recovery, total effective rate and adverse reactions were compared between the two groups. Results:In the treatment group, the time were (2.95±1.32) days when platelet began to rise;the time were (5.86±2.46) days when platelet count returned to normal;the platelet counts were (152.26±65.73)×109L-1 after one week treatment,(212.31±85.26)×109L-1 after two weeks treatment, and (181.72±69.68)×109L-1 after four weeks treatment,which were better than those of the control group[the corresponding values were (5.32±2.65) days, (8.53±3.32) days, (85.72±40.68)×109L-1, (163.58±65.82)×109L-1, (116.43±49.75)×109L-1].The differences were statistically significant (P<0.05).The total effective rate (86.67%) of the treatment group was higher than that of the control group (63.33%) and the difference was statistically significant (P<0.05). One patient occured hypertension as a side effect of hormone in the treatment group while no side effect in the control group, and the difference was not statistically significant (P>0.05). Conclusion:The effectiveness of high-dose dexamethasone in the treatment of children with newly diagnosed ITP is more remarkable than that of conventional dose dexamethasone. Both have slight adverse reactions and good safety.
 ARNOLD D M.Bleeding complications in immune thrombocytopenia[J].ASH Education Program Book,2015,2015(1):237-242.
 WEI Y,JI X,WANG Y,et al.High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia:a prospective multicenter randomized trial[J].Blood,2016,127(3):296-302.
 GÓMEZ-ALMAGUER D,HERRERA-ROJAS M A,JAIME-PÉREZ J C,et al.Eltrombopag and high-dose dexamethasone as frontline treatment for newly diagnosed immune thrombocytopenia in adults[J].Blood,2014,123(25):3906-3908.
 MAZZUCCONI M G,FAZI P,BERNASCONI S,et al.Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura:a GIMEMA experience[J].Blood,2007,109(4):1401-1407.
 MA J,FU L L,CHEN Z P,et al.Clinical study of pulsed high-dose dexamethasone treatment in 38 children with primary immune thrombocytopenic purpura[J].Chinese Journal of Hematology,2016,37(10):912-915.
 LI J,WANG Z,HU S,et al.Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura[J].Immunol Lett,2013,154(1-2):42-48.
 HOU Y,FENG Q,XU M,et al.High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia[J].Blood,2016,127(12):1587-1597.
 LIU Z,WANG M,ZHOU S,et al.Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia[J].J Transl Med,2016,14(1):301.